Back to search
FDAFDA · Food and drugs·Recall number D-1281-2020

Lamotrigine Tablets, USP, 150 mg, 20,000-count bulk container, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA, For repackaging by: AvKare Inc., Pulaski, TN 38478, Bulk Shipment, NDC 59746-247-97.

Published June 3, 2020 · Recall initiated: May 26, 2020

Summary

FDA records drug Class III recall D-1281-2020, published June 3, 2020 and initiated May 26, 2020. Recalling firm: Jubilant Cadista Pharmaceuticals, Inc.; Status: Terminated; Reported quantity: 1,313,333 tablets; Lot: Lot #s 19P0437 & 19P0438, Exp. 09/30/2021. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of Foreign Substance visually consistent with the silica granules present in the desiccant packs utilized during storage of the product.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Jubilant Cadista Pharmaceuticals, Inc.
Distributor
TN
Lot
Lot #s 19P0437 & 19P0438, Exp. 09/30/2021.
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Lamotrigine Tablets, USP, 150 mg, 20,000-count bulk container, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA, For repackaging by: AvKare Inc., Pulaski, TN 38478, Bulk Shipment, NDC 59746-247-97. recalled?

Yes. FDA published recall D-1281-2020 on June 3, 2020. Reported hazard: Presence of Foreign Substance visually consistent with the silica granules present in the desiccant packs utilized during storage of the product.

What should I do if I have this product?

Voluntary: Firm initiated · Letter